FDA IND application for ST-01156 Ph 1 trial in patients with advanced solid tumor and heme malignances
“The FDA’s clearance of our IND for ST-01156 validates the power of SEED’s precision-engineered approach to protein degradation,” said Dr. Lan Huang, Co-Founder, Chairman, and CEO of SEED. “ST-01156 represents a fundamentally new class of medicines with many opportunities for impacting human health. Our near-term strategy is designed to explore several RBM39-dependent cancers, including Ewing sarcoma, neuroblastoma, and KRAS-driven solid tumors, an addressable patient population that exceeds one million worldwide.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines